## *Supplementary material*

*Grajek S, Olasińska-Wiśniewska A, Michalak A, Ritter SS. Triple versus double antithrombotic therapy in patients with atrial fibrillation and stent implantation: a meta-analysis of randomized trials. Kardiol Pol. 2019; 77: 837-845. doi:10.33963/KP.14899*

## Supplementary material

## Table S1. Primary Safety End Points reported in respective trials.

| Trial name | Criteria of bleeding complications |
|---|---|
| WOEST | TIMI major and minor bleeding |
| ISAR TRIPLE | TIMI major and minor bleeding |
| PIONEER AF-PCI | Clinically significant bleeding |
| RE-DUAL PCI | STH major or CRNM bleeding |
| AUGUSTUS | STH major or CRNM bleeding |

## Table S2. Secondary Efficacy End Points reported in respective trials

| Trial name | Major Adverse Cardiac Events |
|---|---|
| WOEST | Composite of death, MI, stroke, target vessel revascularization and stent thrombosis |
| ISAR TRIPLE | Composite of death, MI, ischemic stroke, or stent thrombosis |
| PIONEER AF-PCI | Composite of cardiac death, MI, or stroke |
| RE-DUAL PCI | Composite of death, MI, stroke, systemic embolism, or unplanned revascularization by PCI/CABG |
| AUGUSTUS | All-cause death or ischemic events |

## Table S3. Cumulative Incidence of Primary Safety End Points

| Trial | Safety Dual event | Dual total | Triple event | Triple total |
|---|---|---|---|---|
| WOEST VKA | 39 | 279 | 89 | 284 |
| ISAR-TRIPLE VKA | 35 | 307 | 30 | 307 |
| AUGUSTUS VKA | 123 | 1126 | 210 | 1123 |
| PIONEER AF-PCI Rivaroxaban 15mg | 109 | 696 | 167 | 697 |
| RE-DUAL PCI Dabigatran 110 mg | 151 | 981 | 264 | 981 |
| RE-DUAL PCI Dabigatran 150 mg | 154 | 763 | 196 | 764 |
| AUGUSTUS Apixaban 5mg/2.5mg | 84 | 1143 | 158 | 1145 |

## Table S4. Cumulative Incidence of Secondary Efficacy End Points

| | Cumulative Incidence of Secondary Efficacy End Points | | | |
|---|---|---|---|---|
| Trial | Dual event | Dual total | Triple event | Triple total |
| WOEST VKA | 31 | 279 | 50 | 284 |
| ISAR-TRIPLE VKA | 12 | 307 | 13 | 307 |
| AUGUSTUS VKA | 84 | 1154 | 66 | 1154 |
| PIONEER AF-PCI Rivaroxaban 15mg | 41 | 694 | 36 | 695 |
| RE-DUAL PCI Dabigatran 110 mg | 149 | 981 | 131 | 981 |
| RE-DUAL PCI Dabigatran 150 mg | 90 | 763 | 98 | 764 |
| AUGUSTUS Apixaban 5mg/2.5mg | 72 | 1153 | 71 | 1153 |

**Table S5. Risk of bias of individual studies by Cochrane risk assessment tool.**

| | WOEST | ISAR-TRIPLE | PIONEER AF-PCI | RE-DUAL PCI | Augustus |
|---|---|---|---|---|---|
| Random sequence generation *(Selection bias)* | ⊕ | ⊕ | ⊕ | ⊕ | ⊕ |
| Allocation concealment *(Selection bias*) | ⊕ | ⊕ | ⊕ | ⊕ | ⊕ |
| Blinding of participants and personnel *(Performance bias)* * | ⊕ | ⊕ | ⊕ | ⊕ | ⊕ |
| Incomplete outcome data *(Attrition bias)* | ⊕ | ⊕ | ⊕ | ⊕ | ⊕ |
| Selective reporting *(Reporting bias)* | ⊕ | ⊕ | ⊕ | ⊕ | ⊕ |
| Other sources of bias | ⊕ | ⊕ | ⊕ | ⊕ | ⊕ |

**Figure S1. Funnel plot – risk of publication bias for Safety End Points.**




Egger's test p=0,667

**Figure S2. Funnel plot – risk of publication bias for Safety End Points without ISAR-TRIPLE study.**




Egger's test p=0,245

**Figure S3. Funnel plot – risk of publication bias for Safety End Points –VKA studies.**




Egger's test p=0,769

**Figure S4. Funnel plot – risk of publication bias for Safety End Points –NOAC studies.**




Egger's test p=0,955

**Figure S5. Funnel plot – risk of publication bias for Efficacy End Points.**




Egger's test p=0,355

**Figure S6. Funnel plot – risk of publication bias for Efficacy End Points without ISAR-TRIPLE study.**




Egger's test p=0,301

**Figure S7. Funnel plot – risk of publication bias for Efficacy End Points –VKA studies.**




Egger's test p=0,651

**Figure S8. Funnel plot – risk of publication bias for Efficacy End Points –NOAC studies.**




Egger's test p=0,900